Carfilzomib

Generic Name: Carfilzomib

Brand Names: Kyprolis

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₇N_₅O_₇

CAS Number: 868540-17-4

Unique Ingredient Identifier: 72X6E3J5AR

Background: Carfilzomib is an injectable antineoplastic agent (IV only). Chemically, it is a modified tetrapeptidyl epoxide and an analog of epoxomicin. It is also a selective proteasome inhibitor. FDA approved carfilzomib in July 2012 for the treatment of adults with relapsed or refractory multiple myeloma as monotherapy or combination therapy.

Indication: Carfilzomib is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with lenalidomide and dexamethasone; or dexamethasone; or daratumumab and dexamethasone; or daratumumab and hyaluronidase-fihj and dexamethasone; or isatuximab and dexamethasone. It is also indicated as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy.

Associated Conditions: Relapsed/Refractory Multiple Myeloma (RRMM)

Clinical Trials

Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Cyclophosphamide
Drug: Dexamethasone

First Posted Date: 2013-05-20

Last Posted Date: 2024-11-13

Lead Sponsor: European Myeloma Network B.V.

Target Recruit Count: 63

Registration Number: NCT01857115

Locations: 🇮🇹
Fondazione EMN Italy Onlus, Torino, Italy

Carfilzomib and Melphalan Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

Phase 1

Completed

Conditions: DS Stage I Plasma Cell Myeloma
DS Stage II Plasma Cell Myeloma
DS Stage III Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions: Procedure: Autologous Bone Marrow Transplantation
Procedure: Autologous Hematopoietic Stem Cell Transplantation
Drug: Carfilzomib
Other: Laboratory Biomarker Analysis
Drug: Melphalan

First Posted Date: 2013-04-29

Last Posted Date: 2020-09-01

Lead Sponsor: Mayo Clinic

Target Recruit Count: 50

Registration Number: NCT01842308

Locations: 🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib
Drug: Bortezomib
Drug: Melphalan
Drug: Prednisone

First Posted Date: 2013-03-26

Last Posted Date: 2019-08-26

Lead Sponsor: Amgen

Target Recruit Count: 955

Registration Number: NCT01818752

Locations: 🇺🇸
California Cancer Associates for Research & Excellence, Inc. (cCARE), Fresno, California, United States
🇨🇳
Guangdong General Hospital, Guangzhou, Guangdong, China
🇦🇺
The Alfred Hospital, Melbourne, Victoria, Australia

and more 209 locations

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Active, not recruiting

Conditions: Stage I Multiple Myeloma
Stage II Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: dexamethasone
Drug: carfilzomib
Drug: lenalidomide
Procedure: autologous hematopoietic stem cell transplantation
Other: laboratory biomarker analysis

First Posted Date: 2013-03-22

Last Posted Date: 2024-05-14

Lead Sponsor: University of Chicago

Target Recruit Count: 76

Registration Number: NCT01816971

Locations: 🇺🇸
Washington University in St Louis, Saint Louis, Missouri, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
🇨🇦
Princess Margaret, Toronto, Ontario, Canada

and more 2 locations

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

Phase 2

Completed

Conditions: Waldenstrom Macroglobulinemia

Interventions: Drug: Carfilzomib
Drug: Rituximab
Drug: Dexamethasone

First Posted Date: 2013-03-18

Last Posted Date: 2022-04-13

Lead Sponsor: Hackensack Meridian Health

Target Recruit Count: 7

Registration Number: NCT01813227

Locations: 🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell Transplant

Phase 2

Withdrawn

Conditions: Stage I Multiple Myeloma
Refractory Multiple Myeloma
Stage III Multiple Myeloma
Stage II Multiple Myeloma

Interventions: Drug: carfilzomib
Drug: dexamethasone
Other: laboratory biomarker analysis

First Posted Date: 2013-03-18

Last Posted Date: 2016-12-19

Lead Sponsor: Mayo Clinic

Registration Number: NCT01812720

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma

Phase 1

Conditions: Multiple Myeloma

Interventions: Drug: Carfilzomib and Dexamethasone

First Posted Date: 2013-02-15

Last Posted Date: 2018-03-05

Lead Sponsor: Oncotherapeutics

Target Recruit Count: 38

Registration Number: NCT01792102

Locations: 🇺🇸
John Theuer Cancer Center Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
James R. Berenson M.D. Inc., West Hollywood, California, United States

A Safety Study of Carfilzomib in Patients With Previously-Treated Systemic Light Chain Amyloidosis

Phase 1

Completed

Conditions: Amyloidosis
Systemic Light Chain Amyloidosis

Interventions: Drug: Carfilzomib
Drug: Dexamethasone

First Posted Date: 2013-02-12

Last Posted Date: 2017-10-18

Lead Sponsor: Criterium, Inc.

Target Recruit Count: 32

Registration Number: NCT01789242

Locations: 🇺🇸
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack, New Jersey, United States

and more 7 locations